NASDAQ: TTRXTurn Therapeutics Inc Stock
$3.43+0.05 (+1.48%)
Updated Apr 15, 2026
TTRX Price
$3.43
Fair Value Price
$0.36
Market Cap
$102.17M
52 Week Low
$2.57
52 Week High
$26.50
P/E
-28.58x
P/B
21.8x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$3.19M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.6
Operating Cash Flow
-$3M
Beta
1.3
Next Earnings
May 13, 2026
Ex-Dividend
N/A
Next Dividend
N/A
TTRX Overview
Global Health Solutions, Inc., doing business as Turn Therapeutics, operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic resistance through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses. Global Health Solutions, Inc. was incorporated in 2015 and is based in Westlake Village, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TTRX's potential to beat the market
- TTRX doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
TTRX
RankedUnranked of 462
RankedUnranked of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $23.92 | A | |
| $199.33 | A | |
| $9.44 | A |
Be the first to know about important TTRX news, forecast changes, insider trades & much more!
TTRX News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TTRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TTRX ($3.43) is overvalued by 843.63% relative to our estimate of its Fair Value price of $0.36 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
TTRX ($3.43) is not significantly undervalued (843.63%) relative to our estimate of its Fair Value price of $0.36 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
TTRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TTRX due diligence checks available for Premium users.
Valuation
TTRX fair value
Fair Value of TTRX stock based on Discounted Cash Flow (DCF)
Price
$3.43
Fair Value
$0.36
Overvalued by
843.63%
TTRX ($3.43) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TTRX ($3.43) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TTRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TTRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-28.58x
Industry
26.53x
Market
30.93x
TTRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
21.8x
Industry
5.05x
TTRX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TTRX's financial health
Profit margin
Revenue
$0.0
Net Income
$279.1k
Profit Margin
0%
TTRX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$12.2M
Liabilities
$7.5M
Debt to equity
1.6
TTRX's short-term liabilities ($6.00M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TTRX's short-term assets ($5.20M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TTRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.2M
Investing
-$31.4k
Financing
$3.2M
TTRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TTRX vs Biotech Stocks
Turn Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.